/
Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Why African Americans Must Understand and Participate in Clinical Trials and Vaccines

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines - PowerPoint Presentation

ryotheasy
ryotheasy . @ryotheasy
Follow
343 views
Uploaded On 2020-06-17

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines - PPT Presentation

Virginia A Caine MD Associate Professor of Medicine Division of Infectious Diseases Indiana University School of Medicine Director Marion County Public Health Department Indianapolis Indiana ID: 780269

trials clinical research measles clinical trials measles research patients hiv children dose vaccine immunity disease health prevention united heart

Share:

Link:

Embed:

Download Presentation from below link

Download The PPT/PDF document "Why African Americans Must Understand an..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

Why African Americans Must Understand and Participate in Clinical Trials and Vaccines

Virginia A. Caine, M.D.

Associate Professor of Medicine

Division of Infectious Diseases

Indiana University School of Medicine

Director, Marion County Public Health Department

Indianapolis, Indiana

Slide2

What Are Clinical Trials?

Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for humans. These studies also may show which medical approaches work best for certain illnesses or group of people

.

Slide3

Why are Clinical Trials Needed?

Health care is increasingly reliant on evidence-based medicine.

Significant burden on clinical research to provide the knowledge upon which such evidence is based.

Does a treatment work? Does it work better than other treatments? Does it have any side effects?Clinical trials are designed to answer these questions and improve health and quality of life for patients.

Slide4

Clinical Research

Safety oversight is a major, multilayered challenge for modern clinical research.

Institutional Review Boards (IRBs) has the responsibility to assure that steps are taken to safeguard the rights and welfare of those who agree to be research subjects.

IRBs exist on the local level that include non-scientists, as well as scientists not connected to the research.

Slide5

Clinical Research

In a recent poll of 6,000 cancer patients, 84% were unaware at the time of their diagnosis, that participation in a clinical trial was an option.

A Study reveals

that nearly half of all patients involved in clinical trials, learn

from their physicians, 35% from media, 9 percent from the Internet, and 8% from family or friends.

Slide6

Clinical Research

Most experts believe that there should be a 10-15 % patient participation rate in clinical trials.

In contrast, 80-90% of cancer-afflicted children are enrolled in clinical trials.

Slide7

Progress in the Last Half-Century as a Result of Clinical Trials

Fifty years ago, many treatments did not exist

From 1980-2000, the age-adjusted death rate in the US for coronary heart disease was cut in half

A randomized trial of the Salk polio vaccine in over 600,000 school children has nearly eradicated polio in the U.S.

Slide8

measles

Slide9

Measles can be serious

Ear infections occur in about one out of every 10 children with measles and can result in permanent hearing loss.

About 1 in 4 people in the U.S. who get measles will be hospitalized.

About 1 child out of every 1,000 who get measles will develop encephalitis (swelling of the brain) that can lead to convulsions and can leave the child deaf or with intellectual disability.

As many as one out of every 20 children with measles gets pneumonia the most common cause of death from measles in young children.

Slide10

Measles

PREVENTION

MMR vaccine

Safe and effective

First dose given at 12-15 months;

b

ooster

dose at ages 4-6 years, required before entry to

kindergarten

Approximately 93% immunity following one dose of vaccine, increases to 99% immunity following second dose

Unvaccinated persons or persons without evidence of immunity participating in higher education should receive two doses of MMR vaccine at least 28 days apart

Unvaccinated adults born during or later than 1957 should receive at least one dose of MMR

Persons born before 1957 can be considered to have immunity

Slide11

Progress in the Last Half-Century(continued)

Measles was nearly eliminated by a vaccine tested in clinical trials.

Fatal outcomes and brain infection from measles leading to permanent brain damage were uncommon but devastating complications

.

Slide12

Slide13

Busted!

Slide14

Tuberculosis Prevention

Landmark trial of tuberculosis prevention in a remote community of 7,333 Alaskan natives conducted from 1957-59 by the US Public Health Service resulted in 86 percent community participation

Six years of follow-up showed an average reduction of 60 percent in new, active cases of tuberculosis.

Slide15

Reported TB Cases*

United States, 1982–2008

Year

No. of Cases

*Updated as of May 20, 2009.

Slide16

Slide17

HIV in the United States

More than 1.1 million people in the United States are living with HIV infection, and almost 1 in 6 (15.8%) are unaware of their infection

Gay, bisexual, and other men who have sex with men (MSM), particularly young Black/African American MSM, are most seriously affected by HIV

By race, Blacks/African Americans face the most severe burden of HIV

Source: Centers for Disease Control and Prevention (CDC)

Slide18

Estimated New HIV Infections in the United States, 2010, for the Most Affected Subpopulations

Slide19

Slide20

Antiretroviral Agents 2007

Nucleoside analogues

zidovudine

(AZT, ZDV)

didanosine

(

ddI

)

zalcitabine

(

ddC

)

stavudine

(D4T)

lamivudine (3TC)

abacavir

(ABC)

emtricitabine

(FTC)

tenofovir

(TDF)

Non-nucleoside analogues

nevirapine

(NVP)

delavirdine

(DLV)

efavirenz

(EFV)

Slide21

Antiretroviral Agents 2007

Protease inhibitors

saquinavir

(SQV)

ritonavir (RIT)

indinavir

(IDV)

nelfinavir

(NFV)

amprenavir

(APV)

fosamprenavir

(FOS)

lopinavir

(LPV)

atazanavir

(ATZ)

tipranavir

(TPV)

darunavir

(DRV)

Fusion inhibitors

T20

CCR5 inhibitors

maraviroc

Integrase

inhibitors

raltegravir

Slide22

Why are Clinical Trials Important?

National Heart, Lungs and Blood Institute tested whether hormone therapy (HT) reduced the risk of heart disease in postmenopausal women.

The study found that HT increased the risk of heart disease, risk of stroke and blood clots.

In women who took a combination of estrogen and progestin, the risk of breast cancer also increased.

Slide23

Science and Society

When patients get involved, science succeeds and we all benefit.

The good news is when patients participate they respond favorably to the experience.

Clinical research holds great promise and tremendous opportunities.